Fred M. Teskin

Array ( [id] => 13986473 [patent_doc_number] => 20190062394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => Improved Therapeutic Control of Proteolytically Sensitive, Destabilized Forms of Interleukin-12 [patent_app_type] => utility [patent_app_number] => 15/767298 [patent_app_country] => US [patent_app_date] => 2016-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41060 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15767298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13400037 [patent_doc_number] => 20180251561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA [patent_app_type] => utility [patent_app_number] => 15/760193 [patent_app_country] => US [patent_app_date] => 2016-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15760193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16353098 [patent_doc_number] => 10793599 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-06 [patent_title] => MPHOSPH1-derived peptide, and vaccine including same [patent_app_type] => utility [patent_app_number] => 15/762480 [patent_app_country] => US [patent_app_date] => 2016-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 33121 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 278 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15762480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11395173 [patent_doc_number] => 20170015708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'CHEMOKINE BINDING POLYPEPTIDES FOR TREATING AUTOIMMUNITY, AND INFLAMMATION' [patent_app_type] => utility [patent_app_number] => 15/285492 [patent_app_country] => US [patent_app_date] => 2016-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 19694 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13444143 [patent_doc_number] => 20180273614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => ANTAGONISTS OF IL-17C FOR THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS [patent_app_type] => utility [patent_app_number] => 15/764918 [patent_app_country] => US [patent_app_date] => 2016-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15764918 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393972 [patent_doc_number] => 20170014507 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'ANTI-TUMOR COMPOSITIONS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/282406 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 4403 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15282406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16680744 [patent_doc_number] => 10940200 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-09 [patent_title] => Aluminum based adjuvants for tolerogenic vaccination [patent_app_type] => utility [patent_app_number] => 15/763739 [patent_app_country] => US [patent_app_date] => 2016-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 50 [patent_no_of_words] => 21229 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15763739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11590898 [patent_doc_number] => 20170115307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'ANTIBODIES TO IL-6 AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/276272 [patent_app_country] => US [patent_app_date] => 2016-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 70 [patent_figures_cnt] => 70 [patent_no_of_words] => 79194 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15276272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11528620 [patent_doc_number] => 20170088597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-30 [patent_title] => 'INTERLEUKIN-15 SUPERAGONIST SIGNIFICANTLY ENHANCES GRAFT-VERSUS-TUMOR ACTIVITY' [patent_app_type] => utility [patent_app_number] => 15/273836 [patent_app_country] => US [patent_app_date] => 2016-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 25252 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15273836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13402371 [patent_doc_number] => 20180252728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => PREDICTION OF CLINICAL RESPONSE TO IL23-ANTAGONISTS USING IL23 PATHWAY BIOMARKERS [patent_app_type] => utility [patent_app_number] => 15/759330 [patent_app_country] => US [patent_app_date] => 2016-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15759330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11350260 [patent_doc_number] => 20160369000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => '4-1BB BINDING MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/257715 [patent_app_country] => US [patent_app_date] => 2016-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 30242 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15257715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11348895 [patent_doc_number] => 20160367635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'FUSION MOLECULES AND IL-15 VARIANTS' [patent_app_type] => utility [patent_app_number] => 15/254713 [patent_app_country] => US [patent_app_date] => 2016-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 28959 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15254713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383349 [patent_doc_number] => 20180243216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => CATIONIC LIPOSOMES FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 15/754206 [patent_app_country] => US [patent_app_date] => 2016-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17757 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15754206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13916681 [patent_doc_number] => 10202448 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-12 [patent_title] => Anti-IL-23 antibodies [patent_app_type] => utility [patent_app_number] => 15/228254 [patent_app_country] => US [patent_app_date] => 2016-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 34142 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15228254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393953 [patent_doc_number] => 20170014488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'USE OF PEGYLATED IGF-1 VARIANTS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/220380 [patent_app_country] => US [patent_app_date] => 2016-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 10551 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15220380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11401757 [patent_doc_number] => 20170022294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'COMPOUND TARGETING IL-23A AND B-CELL ACTIVATING FACTOR (BAFF) AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/215690 [patent_app_country] => US [patent_app_date] => 2016-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 36829 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15215690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11324955 [patent_doc_number] => 20160355567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-08 [patent_title] => 'MULTIMERIC IL-15 SOLUBLE FUSION MOLECULES AND METHODS OF MAKING AND USING SAME' [patent_app_type] => utility [patent_app_number] => 15/213991 [patent_app_country] => US [patent_app_date] => 2016-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 82 [patent_figures_cnt] => 82 [patent_no_of_words] => 42994 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15213991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11114959 [patent_doc_number] => 20160311931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'BISPECIFIC ANTIBODIES THAT NEUTRALIZE BOTH TNF-ALPHA AND IL-6: NOVEL THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE' [patent_app_type] => utility [patent_app_number] => 15/206571 [patent_app_country] => US [patent_app_date] => 2016-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 21662 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15206571 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11401741 [patent_doc_number] => 20170022279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'METHODS OF INHIBITING TUMOR GROWTH BY ANTAGONIZING IL-6 RECEPTOR' [patent_app_type] => utility [patent_app_number] => 15/204639 [patent_app_country] => US [patent_app_date] => 2016-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10527 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15204639 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11311744 [patent_doc_number] => 20160347853 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'TLR3 BINDING AGENTS' [patent_app_type] => utility [patent_app_number] => 15/204851 [patent_app_country] => US [patent_app_date] => 2016-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 37603 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15204851 [rel_patent_id] =>[rel_patent_doc_number] =>)